

PRODUCT INFORMATION




HLA-DR (human) Immunoaffinity Resin (Clone L243)

Item No. 44917

Overview and Properties

Contents:	This vial contains 200 μ l of Sepharose (100 μ l bead volume) coupled to 0.2 mg of an HLA-DR monoclonal antibody (Clone L243)
Synonyms:	HLA Class II Histocompatibility Antigen DR Immunoaffinity Resin, HLA-DR Immunoaffinity Beads, HLA-DR Immunoaffinity Sorbent, MHC Class II Antigen DR Immunoaffinity Resin
Cross Reactivity:	(+) HLA-DR
Species Reactivity:	(+) Human, canine, primate
Form:	Slurry
Storage:	4°C (as supplied)
Stability:	\geq 2 years
Storage Buffer:	PBS, pH 7.2, with 0.02% sodium azide
Clone:	L243
Host:	Mouse
Isotype:	IgG _{2a}
Applications:	Suitable for immunoprecipitation (IP), working concentration/dilution should be determined empirically.

Image



Left: Control HLA-DR-null HL-60 and HLA-DR overexpressing HL-60 were lysed and incubated overnight with 100 μ l HLA-DR (human) Immunoaffinity Resin (Clone L243). The mixture was centrifuged at 500 \times g for 5 minutes and the supernatant was recovered (white bars) and compared with lysate (black bars) in the HLA-DR (α and β chains) ELISA Kit (Item No. 501810). Loss of HLA-DR in the supernatant indicates successful capture of HLA complexes on the resin.

Right: Peptides eluted from the captured HLA complexes were subjected to mass spec, which identified 1,753 peptides in the HLA-expressing cells. The sequences of those peptides align favorably with the consensus binding motif of HLA-DRB1*04:01.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/13/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

HLA-DR is a MHC Class II cell surface receptor heterodimer composed of a 33-35 kDa α chain, a ~30 kDa β chain, and a 10-30 amino acid ligand.¹ When the heterodimer is fully combined on the cell surface of an antigen-presenting cell, such as macrophages, B cells, and dendritic cells, they present that ligand primarily to CD-4⁺ T cells.² This presentation coupled with the T cell response can stimulate or suppress an antibody response to that ligand. HLA-DRs have been linked to a number of autoimmune disorders such as rheumatoid arthritis, lupus, and psoriasis as well as diabetes, hepatitis, and multiple sclerosis among a number of others.³⁻⁹ Cayman's HLA-DR (human) Immunoaffinity Resin (Clone L243) is designed for immunoprecipitation (IP) of HLA-DR from biological samples. IP is a portion of the MHC-II-associated peptide proteomics (MAPPs) procedure used to identify immunogenic epitopes from pathogens, cancers, and biologic drugs. The HLA-DR immunoaffinity resin consists of Cayman's HLA-DR Monoclonal Antibody (Clone L243) (Item No. 21827) coupled to Sepharose.

References

1. Brodsky, F.M. and Parham, P. Monomorphic anti-HLA-A,B,C monoclonal antibodies detecting molecular subunits and combinatorial determinants. *J. Immunol.* **128(1)**, 129-135 (1982).
2. Denzin, L.K., Hammond, C., and Cresswell, P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. *J. Exp. Med.* **184(6)**, 2153-2165 (1996).
3. Panayi, G.S., Wooley, P., and Batchelor, J.R. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. *Br. Med. J.* **2(6148)**, 1326-1328 (1978).
4. Messner, R.P., De Horatius, R., and Ferrone, S. Lymphocytotoxic antibodies in systemic lupus erythematosus patients and their relatives: reactivity with the HLA antigenic molecular complex. *Arthritis Rheum.* **23(3)**, 265-272 (1980).
5. Tsuji, K., Inouye, H., Nose, Y., et al. Further study on HLA-A, B, C, D, DR and haplotype antigen frequencies in psoriasis vulgaris. *Acta. Derm. Venereol. Suppl. (Stockh.)* **87**, 107-108 (1979).
6. Solow, H., Hidalgo, R., and Singal, D.P. Juvenile-onset diabetes HLA-A, -B, -C, and -DR alloantigens. *Diabetes* **28(1)**, 1-4 (1979).
7. Mackay, I.R. and Tait, B.D. HLA associations with autoimmune-type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies. *Gastroenterology* **79(1)**, 95-98 (1980).
8. Luckey, D., Bastakoty, D., and Mangalam, A.K. Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: Studies using HLA transgenic mice. *J. Autoimmun.* **37(2)**, 122-128 (2011).
9. Gorodezky, C., Alaez, C., Murguía, A., et al. HLA and autoimmune diseases: Type 1 diabetes (T1D) as an example. *Autoimmun. Rev.* **5(3)**, 187-194 (2006).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM